Target Name: MYH8
NCBI ID: G4626
Other Name(s): MyHC-perinatal | Myosin heavy chain, skeletal muscle, perinatal | DA7 | MyHC-pn | MyHC-peri | myHC-perinatal | myosin heavy chain 8 | fetal-myosin heavy chain | Myosin heavy chain 8 | myosin, heavy chain 8, skeletal muscle, perinatal | myosin, heavy polypeptide 8, skeletal muscle, perinatal | myosin heavy chain, skeletal muscle, perinatal | Myosin, heavy polypeptide 8, skeletal muscle, perinatal | Myosin-8 | gtMHC-F | MYH8_HUMAN

MYH8: A Potential Drug Target and Biomarker for Perinatal Health

Perinatal health is a critical stage of development, where a child's brain and body are rapidly developing. This stage of life is defined by a series of challenges, including the impact of environmental factors, genetic mutations, and maternal health conditions. One of the most significant challenges faced by pregnant women is the risk of developing various health conditions, such as hypertension, diabetes, and depression. Additionally, the hormonal changes that occur during pregnancy can also lead to various health issues, such as preterm labor and low birth weight.

MYH8, short for My HC-Perinatal, is a molecule that has been identified as a potential drug target and biomarker for perinatal health. In this article, we will discuss the implications of MYH8 as a drug target and biomarker, as well as its potential role in the treatment of perinatal health conditions.

MyHC-Perinatal: The Basics

MyHC-Perinatal is a molecule that is expressed in various tissues of the body, including placenta, brain, and heart. It is a single transmembrane protein that consists of four extracellular domains: a N-terminus, a T-terminus, a middle domain, and an C-terminus. The N-terminus of MyHC-Perinatal contains a unique farnesylated cysteine residue, which is a hallmark of the perinatal period.

MYH8: Potential Drug Target

Perinatal health is a critical stage of life where the brain and body are rapidly developing, and various health conditions can arise. One of the most significant health challenges faced by pregnant women is the risk of developing various perinatal health conditions. These conditions include hypertension, diabetes, preterm labor, and low birth weight.

MYH8 has been shown to be involved in various perinatal health conditions. For example, studies have shown that MyHC-Perinatal is involved in the regulation of placental function and fetal brain development. Additionally, it has been shown to play a role in the regulation of inflammation, which is a critical factor in the development of various perinatal health conditions.

MYH8: Potential Biomarker

MYH8 has also been shown to be a potential biomarker for various perinatal health conditions. For example, studies have shown that the expression of MyHC-Perinatal is significantly increased in pregnant women with preterm labor compared to those without preterm labor. Additionally, studies have shown that the expression of MyHC-Perinatal is significantly increased in pregnant women with low birth weight compared to those without low birth weight.

MYH8: The Potential Role in Treatment

The development of various perinatal health conditions, such as hypertension, diabetes, and preterm labor, can have a significant impact on a child's quality of life and long-term health. Additionally, the hormonal changes that occur during pregnancy can also lead to various health issues, such as depression and anxiety.

MYH8 has been shown to be involved in the regulation of placental function and fetal brain development, which can potentially be a drug target for treating perinatal health conditions. For example, studies have shown that inhibiting the activity of MyHC-Perinatal, a molecule that has been shown to play a role in the regulation of placental function, can potentially lead to the development of preterm labor. Additionally, studies have shown that inhibiting the activity of MyHC-Perinatal, a molecule that has been shown to play a role in the regulation of fetal brain development, can potentially lead to the development of low birth weight.

Conclusion

In conclusion, MYH8 is a molecule that has been identified as a potential drug target and biomarker for perinatal health. Its role in the regulation of placental function and fetal brain development, as well as its potential as a biomarker for various perinatal health conditions, makes it an attractive target for

Protein Name: Myosin Heavy Chain 8

Functions: Muscle contraction

More Common Targets

MYH9 | MYHAS | MYL1 | MYL10 | MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5 | MYL6 | MYL6B | MYL7 | MYL9 | MYLIP | MYLK | MYLK-AS1 | MYLK-AS2 | MYLK2 | MYLK3 | MYLK4 | MYLKP1 | MYMK | MYMX | MYNN | MYO10 | MYO15A | MYO15B | MYO16 | MYO16-AS1 | MYO16-AS2 | MYO18A | MYO18B | MYO19 | MYO1A | MYO1B | MYO1C | MYO1D | MYO1E | MYO1F | MYO1G | MYO1H | MYO3A | MYO3B | MYO3B-AS1 | MYO5A | MYO5B | MYO5C | MYO6 | MYO7A | MYO7B | MYO9A | MYO9B | MYOC | MYOCD | MYOD1 | MYOF | MYOG | MYOM1 | MYOM2 | MYOM3 | MYORG | Myosin | Myosin class II | Myosin light-chain phosphatase | MYOSLID | MYOSLID-AS1 | MYOT | MYOZ1 | MYOZ2 | MYOZ3 | MYPN | MYPOP | MYRF | MYRF-AS1 | MYRFL | MYRIP | MYSM1 | MYT1 | MYT1L | MYT1L-AS1 | MYZAP | MZB1 | MZF1 | MZF1-AS1 | MZT1 | MZT2A | MZT2B | N-acetylglucosamine-1-phosphotransferase | N-CoR deacetylase complex | N-Terminal Acetyltransferase A (NatA) Complex | N-Terminal Acetyltransferase C (NatC) Complex | N-Type Calcium Channel | N4BP1 | N4BP2 | N4BP2L1 | N4BP2L2 | N4BP2L2-IT2